Author's posts
Senators Agree Surprise Medical Bills Must Go. But How?
The Senate Health, Education, Labor and Pensions Committee is scheduled next week to mark up a massive legislative package on curbing health costs, but some of the details remain unresolved, including what formula to use to pay doctors and hospitals involved in surprise medical bills.
Air Ambulance Costs Fly Around Fixes For Surprise Medical Bills
The median cost of an air ambulance bill is more than $36,000 and seldom covered by insurance, sparking many consumer complaints. Yet none of the proposals introduced or circulating in Congress to fix surprise medical bills address these services.
Sen. Alexander Releases Bipartisan Plan To Lower Health Costs, End Surprise Bills
The Republican’s legislation, prepared with Sen. Patty Murray, the ranking Democrat on Alexander’s health committee, would be an ambitious lift because it also deals with prescription drug patents, health transparency and vaccine messaging.
Are Surprises Ahead For Legislation To Curb Surprise Medical Bills?
This high-profile issue has gained bipartisan attention, but it remains unclear if that’s enough to move it to the finish line. Here’s a review of the current state of play.
Are Surprises Ahead For Legislation To Curb Surprise Medical Bills?
This high-profile issue has gained bipartisan attention, but it remains unclear if that’s enough to move it to the finish line. Here’s a review of the current state of play.
Is It A Feminist Right To Want More Sex? One Company Thinks A Pill Is The Answer
The savvy “Right to Desire” campaign relies on feminist messages and social media to raise patient awareness about low libido. Addyi, the only drug currently approved to treat it, has shown limited effectiveness.
Drug Industry Patents Go Under Senate Judiciary Committee’s Microscope
During a hearing Tuesday, panel members focused on how drug companies have used patents to allegedly protect their competitive edge and profits.
The Blame Game: Everyone And No One Is Raising Insulin Prices
During Wednesday’s House subcommittee hearing on insulin price hikes, drug makers and benefits managers pointed fingers at each other for the last decade’s 300% price increase, frustrating congressional representatives.
Can Someone Tell Me What A PBM Does?
The Senate Finance Committee’s third drug-pricing hearing focused on pharmacy benefit managers, and was more of a fact-finding mission on how these companies operate than a debate about policy proposals.
Fixing Surprise Medical Bill Problem Shouldn’t Fall To Consumers, Panel Told
Though a range of policy solutions have been discussed by Congress, the White House and other experts, a theme of a House subcommittee hearing Tuesday was that providers and insurers are key to correcting the issue.
